Latest news with #GMP
Time of India
9 hours ago
- Business
- Time of India
HDB Financial's Rs 12,500 crore IPO: 10 key facts investors should know before June 25
Investor interest is building around the upcoming initial public offering of HDB Financial Services , the non-banking finance arm backed by HDFC Bank . At Rs 12,500 crore, the long-awaited issue is poised to be the largest of 2025 so far, drawing attention from both institutional players and retail participants. As the subscription window nears, here are 10 key facts investors should know. 1. GMP points to strong debut As of June 20, the grey market premium for HDB Financial stood at Rs 83, implying a listing price of Rs 823, an 11.22% premium to the issue's upper band. Market watchers note the GMP trend has been upward in recent sessions, signalling expectations of a firm listing. 2. The largest IPO of the year to date With a total issue size of Rs 12,500 crore, HDB Financial's IPO is set to be the biggest in 2025 so far. It also ranks as the largest public offering since Hyundai Motor India's Rs 27,000 crore IPO last year. 3. HDB Financial Services IPO price band The price band for the issue has been fixed at Rs 700 to Rs 740 per share. Investors are advised to consider bidding at the cut-off to improve allocation chances in the event of oversubscription. 4. Subscription window The IPO will open for subscription on Tuesday, June 25, and close on Thursday, June 27. The basis of allotment is expected to be finalised on Monday, June 30. 5. Tentative listing Shares of HDB Financial are expected to list on both the BSE and NSE on Wednesday, July 2, subject to final regulatory approvals. 6. Offer structure The IPO comprises a fresh issue of Rs 2,500 crore and an offer for sale worth Rs 10,000 crore by HDFC Bank, which currently holds a 94.6% stake in the company. The share sale forms part of the bank's broader capital optimisation strategy. 7. Quotas reserved The issue includes reserved portions for eligible employees of HDB Financial as well as shareholders of parent HDFC Bank . 8. Application sizes and investment requirements Retail investors can apply for a minimum of 20 shares, amounting to Rs 14,000 at the lower band and Rs 14,800 at the upper band. For small non-institutional investors applicants, the minimum investment is Rs 2,07,200 (14 lots); for big non-institutional investors, it is Rs 10,06,400 (68 lots). 9. Managed by a consortium of global and domestic banks The IPO is being led by a 13-member syndicate of book-running lead managers, including BofA Securities India, Goldman Sachs (India), Morgan Stanley, JM Financial , Motilal Oswal, and others. MUFG Intime India (Link Intime) is the registrar. 10. Key player in India's NBFC sector HDB Financial Services operates across retail and commercial lending segments, offering products such as personal loans, vehicle loans, gold loans, and loans against property. The company has a wide presence in semi-urban and rural markets, and intends to use the fresh issue proceeds to bolster capital adequacy and support lending growth. Also read | HDFC Bank shares in focus as Rs 12,500-crore HDB Financial IPO opens next week ( Disclaimer : Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of the Economic Times)
&w=3840&q=100)
Business Standard
19 hours ago
- Business
- Business Standard
Ellenbarrie sets IPO price at ₹380-400; Arisinfra subscribed 1.3x on Day 2
Ellenbarrie sets IPO price at ₹380 -400 Ellenbarrie Industrial Gases has priced its initial public offering (IPO) between ₹380-400 per share. The IPO will open on Tuesday and close on Thursday. The ₹852 crore IPO is a mix of fresh issue worth ₹400 crore and an offer for sale of ₹452 crore. ALSO READ: Real estate giant Kalpataru eyes deleveraging amid ₹1,590 cr IPO Day 2: Arisinfra IPO subscribed 1.3 x The IPO of Arisinfra Solutions was subscribed 1.3 times on Thursday, the penultimate day of the issue. The institutional investor portion was subscribed 0.7 times, the wealthy investor portion by 1.4 times, and the retail investor portion by 3 times. ALSO READ: Influx Healthtech IPO Day 2 update: Subscription rises 16x, GMP at 47% Capillary Tech India files for IPO Capillary Technologies India, a company that offers artificial intelligence-based cloud-native SaaS products, refiled its draft red herring prospectus to raise funds for its initial public offering (IPO). The IPO comprises an issue of equity shares aggregating to ₹430 crore. ALSO READ: Oswal Pumps IPO listing forecast: Here's what the latest GMP hints at
India Today
a day ago
- Business
- India Today
Oswal Pumps IPO listing: Will it make a bumper debut? Check latest GMP
Oswal Pumps is poised to make its stock market debut on June 20, amid strong anticipation from investors looking for a bumper debut on Dalal allotment for the initial public offering (IPO) of Oswal Pumps was finalised on June 18, 2025, after attracting substantial interest despite initial slow IPO of Oswal Pumps was oversubscribed by more than 34 times, indicating strong confidence from investors, especially among Qualified Institutional Buyers (QIBs) and Non-Institutional Investors (NIIs). This response underscores the institutional trust in the company's fundamental strength and its projected long-term growth prospects, even in the face of market The price band for the IPO was fixed between Rs 584 and Rs 614 per share. The minimum lot size was 24 shares. For retail investors, this meant a minimum investment of Rs 14,016 at the lower end of the price band. However, most retail investors prefer bidding at the cut-off price, which required an investment of Rs 14,736."We believe this overwhelming demand was driven by attractive valuation levels, offering reasonable long-term upside potential along with a well-diversified product portfolio across agriculture, industrial, and domestic water solutions. We also see the company's strategic positioning to benefit from ongoing government infrastructure and rural development initiatives, especially those focused on water management and irrigation," said Prashanth Tapse, Senior VP (Research) at Mehta Equities experts are optimistic about the listing, expecting a gain in the range of 10–15% based on current market sentiment and the strong subscription estimated listing price is Rs 662, factoring in the current Grey Market Premium (GMP). However, the GMP has seen a decline recently, falling from Rs 60 during allotment to Rs 48 as of June 19."Given the strong subscription demand and ongoing market sentiment, we anticipate a decent listing gain in the range of 10–15% for Oswal Pumps debut. The IPO saw significant oversubscription, reflecting confidence in the company's fundamentals and valuation. We view Oswal Pumps as a compelling long-term investment opportunity, well-aligned with the government's continued emphasis on rural electrification and promotion of solar-powered irrigation systems," added investors who have been allotted shares, holding onto the investment is advised due to the strong structural growth prospects in the agriculture and infrastructure sectors. The company is seen as well-positioned to benefit from sectoral growth drivers."For Allotted investors: We advise a HOLD for the long term, as the company is well-positioned to benefit from structural growth drivers in the agri and infrastructure sectors. For Non-allotted investors: Consider accumulating on any dips post-listing, particularly if broader market sentiment causes short-term volatility. The business offers a strong combination of sectoral tailwinds and value-based fundamentals," he advised will be keenly watching the debut, hoping for a favourable outcome that aligns with the optimistic projections.
Mint
a day ago
- Business
- Mint
HDFC Mutual Fund raises stake in Glenmark Pharmaceuticals to 5.07%. Details here
HDFC Mutual Fund has increased its stake in Glenmark Pharmaceuticals, breaching the 5 percent ownership threshold, as per the company's regulatory filing on June 18, 2025. The move comes even as Glenmark disclosed recent regulatory scrutiny of its U.S. manufacturing facility by the United States Food and Drug Administration (USFDA). According to the filing, HDFC Mutual Fund purchased an additional 3.57 lakh equity shares of Glenmark Pharma, raising its holding by 0.13 percent. Prior to the transaction, the fund house held 1.39 crore shares, or 4.94 percent of the company. Post acquisition, its total shareholding stands at 1.43 crore shares, which translates to a 5.07 percent stake in the pharmaceutical major. The stake increase is seen as a mark of confidence in the company's fundamentals and long-term growth potential, especially amid recent regulatory developments. As per the March 2025 shareholding pattern, Glenmark's promoters continue to hold a dominant 46.65 percent stake in the company. In parallel with the stake hike, Glenmark Pharmaceuticals also updated the stock exchanges about a recent Good Manufacturing Practice (GMP) inspection conducted by the USFDA at its Monroe, North Carolina facility in the U.S. The inspection, which spanned from June 9 to June 17, 2025, culminated in the issuance of a Form 483 with five observations. The company was quick to clarify that the observations were procedural in nature and did not pertain to data integrity—an issue that often raises red flags in the pharmaceutical industry. In its exchange communication, Glenmark stated, 'The Company will work in close collaboration with the agency to address the observations and will respond to the USFDA within the stipulated timeline.' A Form 483 is typically issued when the FDA investigator identifies possible violations of the Food, Drug, and Cosmetic (FD&C) Act, but the absence of critical concerns such as data falsification is considered a relatively positive outcome. On the market front, Glenmark Pharma shares saw some volatility, falling by as much as 1.5 percent to touch a low of ₹ 1,634.55 on June 18. The stock is still around 11 percent below its 52-week high of ₹ 1,830.05, which it had touched in October 2025. However, it remains significantly above its 52-week low of ₹ 1,199.95, seen in June 2024. The recent price trajectory shows renewed investor interest, with the stock gaining 12.5 percent in June so far, following a 5.5 percent rise in May. This follows a choppy start to the year where the stock fell over 10 percent in April, surged 20.5 percent in March, and posted losses of 12 percent and 9.7 percent in February and January respectively. Disclaimer: The views and recommendations made above are those of individual analysts or broking companies, and not of Mint. We advise investors to check with certified experts before making any investment decisions.
Business Standard
a day ago
- Business
- Business Standard
Zydus Life Matoda facility receives two observations from USFDA after inspection
Zydus Lifesciences announced that its oncology injectable manufacturing facility located at SEZ 1 near Matoda, Ahmedabad, has received two observations from the United States Food and Drug Administration (USFDA) following a recent inspection. In a regulatory filing, the company confirmed that the USFDA conducted a follow-up inspection focused on good manufacturing practices (GMP) from 9 June to 18 June 2025. Upon conclusion of the inspection, the US health regulator issued two observations. Zydus clarified that the observations are not related to data integrity. The company further stated that it will work closely with the USFDA to address the issues raised and will submit its response within an expeditious manner. Zydus Lifesciences is a discovery-driven, global life sciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies. The companys consolidated net profit shed 0.96% to Rs 1,170.9 crore on a 17.21% rise in revenue from operations to Rs 6,290.2 crore in Q4 FY25 over Q4 FY24. The counter shed 0.40% to Rs 954 on the BSE.
